Silexion Therapeutics Corp (SLXN)Healthcare | Biotechnology | Jerusalem, Israel | NasdaqCM
2.50 USD
-0.09
(-3.475%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.50 |
Hot Take ↕ | July 11, 2026, 5:22 a.m. EDT
The immediate outlook is severely compromised by a catastrophic multi-year price collapse. While the company recently posted clinical milestones and secured financing, the market has punished the stock with a 93.5% drop in the trailing twelve months, leaving it trading near its 52-week low. This deep discount reflects a complete loss of investor confidence in the current business model, exacerbated by a precarious balance sheet where debt significantly outweighs equity and cash burn is accelerating. The recent reverse split suggests management is attempting to engineer liquidity, but without a proven path to profitability or a dominant market position, the risk of permanent capital impairment remains extreme. Furthermore, the absence of any dividend history confirms this is a pure speculative vehicle with no income floor. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.131166 |
| AutoTheta | 0.145039 |
| AutoETS | 0.476400 |
| MSTL | 0.873391 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 0.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 683.505 |
| Market Cap | 2,657,792 |
| Forward P/E | -3.91 |
| Beta | -0.26 |
| Website | https://silexion.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9778348 |
| Address1 | The Goldyne Savad Inst. of Gene Therapy |
| Address2 | Hadassah Hebrew Univ Medical Ctr |
| All Time High | 2,033.7 |
| All Time Low | 2.31 |
| Ask | 3.23 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 28,430 |
| Average Daily Volume3 Month | 649,449 |
| Average Volume | 649,449 |
| Average Volume10Days | 28,430 |
| Beta | -0.26 |
| Bid | 1.82 |
| Bid Size | 2 |
| Book Value | 0.857 |
| City | Jerusalem |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.5 |
| Current Ratio | 1.001 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.58 |
| Day Low | 2.5 |
| Debt To Equity | 683.505 |
| Display Name | Silexion Therapeutics |
| Earnings Timestamp End | 1,754,596,800 |
| Earnings Timestamp Start | 1,754,596,800 |
| Ebitda | -12,719,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.049 |
| Enterprise Value | 623,487 |
| Eps Forward | -0.64 |
| Eps Trailing Twelve Months | -59.7 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 2 643 0982 |
| Fifty Day Average | 4.0131 |
| Fifty Day Average Change | -1.5131001 |
| Fifty Day Average Change Percent | -0.3770402 |
| Fifty Two Week Change Percent | -97.783485 |
| Fifty Two Week High | 223.6 |
| Fifty Two Week High Change | -221.1 |
| Fifty Two Week High Change Percent | -0.9888193 |
| Fifty Two Week Low | 2.31 |
| Fifty Two Week Low Change | 0.19000006 |
| Fifty Two Week Low Change Percent | 0.08225111 |
| Fifty Two Week Range | 2.31 - 223.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,617,802,200,000 |
| Float Shares | 414,621 |
| Forward Eps | -0.64 |
| Forward P E | -3.90625 |
| Free Cashflow | -7,491,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.24163 |
| Held Percent Institutions | 0.01792 |
| Implied Shares Outstanding | 1,063,117 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-08-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,780,012,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel. |
| Long Name | Silexion Therapeutics Corp |
| Market | us_market |
| Market Cap | 2,657,792 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_134350646 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -12,910,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,753,473 |
| Number Of Analyst Opinions | 2 |
| Open | 2.58 |
| Operating Cashflow | -12,012,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 2 674 3430 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.5 |
| Post Market Time | 1,783,984,090 |
| Previous Close | 2.59 |
| Price Hint | 4 |
| Price To Book | 2.917153 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.594 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.089999914 |
| Regular Market Change Percent | -3.4749002 |
| Regular Market Day High | 2.58 |
| Regular Market Day Low | 2.5 |
| Regular Market Day Range | 2.5 - 2.58 |
| Regular Market Open | 2.58 |
| Regular Market Previous Close | 2.59 |
| Regular Market Price | 2.5 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 13,717 |
| Return On Assets | -1.23267 |
| Return On Equity | -8.97463 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,063,117 |
| Shares Percent Shares Out | 0.0128999995 |
| Shares Short | 13,737 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 154,973 |
| Short Name | Silexion Therapeutics Corp |
| Short Percent Of Float | 0.0156 |
| Short Ratio | 0.07 |
| Source Interval | 15 |
| Symbol | SLXN |
| Target High Price | 60.0 |
| Target Low Price | 60.0 |
| Target Mean Price | 60.0 |
| Target Median Price | 60.0 |
| Total Cash | 2,413,000 |
| Total Cash Per Share | 5.759 |
| Total Debt | 1,989,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -59.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.013124 |
| Two Hundred Day Average Change | -15.513124 |
| Two Hundred Day Average Change Percent | -0.8612123 |
| Type Disp | Equity |
| Volume | 13,717 |
| Website | https://silexion.com |
| Zip | 9,112,001 |